205 related articles for article (PubMed ID: 30654348)
21. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells.
Liu H; Zhang Z; Chi X; Zhao Z; Huang D; Jin J; Gao J
Sci Rep; 2016 Aug; 6():31009. PubMed ID: 27484730
[TBL] [Abstract][Full Text] [Related]
22. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
23. Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
Park W; Chen J; Cho S; Park SJ; Larson AC; Na K; Kim DH
ACS Appl Mater Interfaces; 2016 May; 8(20):12711-9. PubMed ID: 27159350
[TBL] [Abstract][Full Text] [Related]
24. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma.
Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L
Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436
[TBL] [Abstract][Full Text] [Related]
25. Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Sun J; Cheng M; Ye T; Li B; Wei Y; Zheng H; Zheng H; Zhou M; Piao JG; Li F
Nanomedicine (Lond); 2022 Nov; 17(26):2037-2054. PubMed ID: 36789952
[TBL] [Abstract][Full Text] [Related]
26. Improved anticancer efficacy of epirubicin by magnetic mesoporous silica nanoparticles: in vitro and in vivo studies.
Ansari L; Jaafari MR; Bastami TR; Malaekeh-Nikouei B
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):594-606. PubMed ID: 29688064
[TBL] [Abstract][Full Text] [Related]
27. High drug loading and pH-responsive targeted nanocarriers from alginate-modified SPIONs for anti-tumor chemotherapy.
Peng N; Wu B; Wang L; He W; Ai Z; Zhang X; Wang Y; Fan L; Ye Q
Biomater Sci; 2016 Nov; 4(12):1802-1813. PubMed ID: 27792228
[TBL] [Abstract][Full Text] [Related]
28. Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Xie M; Xu Y; Shen H; Shen S; Ge Y; Xie J
Int J Pharm; 2014 Oct; 474(1-2):223-31. PubMed ID: 25149125
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe
Shen JM; Li XX; Fan LL; Zhou X; Han JM; Jia MK; Wu LF; Zhang XX; Chen J
Int J Nanomedicine; 2017; 12():1183-1200. PubMed ID: 28243083
[TBL] [Abstract][Full Text] [Related]
30. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional PEG modified DOX loaded mesoporous silica nanoparticle@CuS nanohybrids as photo-thermal agent and thermal-triggered drug release vehicle for hepatocellular carcinoma treatment.
Wu L; Wu M; Zeng Y; Zhang D; Zheng A; Liu X; Liu J
Nanotechnology; 2015 Jan; 26(2):025102. PubMed ID: 25517859
[TBL] [Abstract][Full Text] [Related]
32. Arsenite-loaded nanoparticles inhibit the invasion and metastasis of a hepatocellular carcinoma: in vitro and in vivo study.
Chi X; Yin Z; Jin J; Li H; Zhou J; Zhao Z; Zhang S; Zhao W; Xie C; Li J; Feng M; Lin H; Wang X; Gao J
Nanotechnology; 2017 Nov; 28(44):445101. PubMed ID: 28829335
[TBL] [Abstract][Full Text] [Related]
33. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
34. Thermal and pH responsive polymer-tethered multifunctional magnetic nanoparticles for targeted delivery of anticancer drug.
Sahoo B; Devi KS; Banerjee R; Maiti TK; Pramanik P; Dhara D
ACS Appl Mater Interfaces; 2013 May; 5(9):3884-93. PubMed ID: 23551195
[TBL] [Abstract][Full Text] [Related]
35. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
36. Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release.
Zou Z; He X; He D; Wang K; Qing Z; Yang X; Wen L; Xiong J; Li L; Cai L
Biomaterials; 2015 Jul; 58():35-45. PubMed ID: 25941780
[TBL] [Abstract][Full Text] [Related]
37. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
[TBL] [Abstract][Full Text] [Related]
38. Thiolated chitosan nanoparticles for stable delivery and smart release of As
Song X; Wu J; Song W; Chen L; Zhang S; Ji H; Liu J; Gu J
Carbohydr Polym; 2023 Mar; 303():120462. PubMed ID: 36657859
[TBL] [Abstract][Full Text] [Related]
39. Angiopep-2-Conjugated "Core-Shell" Hybrid Nanovehicles for Targeted and pH-Triggered Delivery of Arsenic Trioxide into Glioma.
Tao J; Fei W; Tang H; Li C; Mu C; Zheng H; Li F; Zhu Z
Mol Pharm; 2019 Feb; 16(2):786-797. PubMed ID: 30620881
[TBL] [Abstract][Full Text] [Related]
40. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles.
Liu Q; Li R; Zhu Z; Qian X; Guan W; Yu L; Yang M; Jiang X; Liu B
Int J Pharm; 2012 Jul; 430(1-2):350-8. PubMed ID: 22525076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
